[pubmed] Thymomatous Myasthenia Gravis: 10-year Experience of a Single Center
Posté : 07 août 2020 12:00
Acta Neurol Scand. 2020 Aug 6. doi: 10.1111/ane.13332. Online ahead of print.
ABSTRACT
OBJECTIVES: To summarize the clinical features of thymomatous myasthenia gravis (T-MG), examine the association between MG and thymoma, and identify the related factors or predictors for long-term prognosis of T-MG.
METHODS: A retrospective, observational study was conducted on 100 patients with T-MG and 96 patients with non-T-MG (NT-MG) between January 1, 2009 and December 31, 2019. The baseline characteristics were recorded for each patient. Logistic regression was used to measure the association between all clinical variables and T-MG prognosis.
RESULTS: Between the T-MG and NT-MG groups, age at onset (45.66±11.53 years vs. 39.06±14.39 years); age >40 years (72.0% vs. 40.6%); AChR-Ab positive rate (100.0% vs. 83.3%); Myasthenia Gravis Foundation of America (MGFA) classification at the worst condition (≥grade III, 61.0% vs. 33.0%); thyroid dysfunction (7.0% vs. 20.8%); and outcome (complete stable remission+pharmacologic remission+improvement, 74.0% vs. 93.7%) were statistically significant (P
Source: https://pubmed.ncbi.nlm.nih.gov/3276206 ... 7&v=2.11.4